AstraZeneca PLC (AZN)vsElectromed Inc (ELMD)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
ELMD
Electromed Inc
$27.25
+2.25%
HEALTHCARE · Cap: $226.72M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 83079% more annual revenue ($61.37B vs $73.78M). AZN leads profitability with a 17.0% profit margin vs 15.3%. ELMD appears more attractively valued with a PEG of 0.35. ELMD earns a higher WallStSmart Score of 70/100 (B-).
AZN
Buy60
out of 100
Grade: C+
ELMD
Strong Buy70
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
-55.2%
Fair Value
$16.28
Current Price
$27.25
$10.97 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Growing faster than its price suggests
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 21 in profit
Earnings expanding 49.0% YoY
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : ELMD
The strongest argument for ELMD centers on PEG Ratio, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 15.3% and operating margin at 19.7%. Revenue growth of 11.6% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : ELMD
The primary concerns for ELMD are Market Cap.
Key Dynamics to Monitor
ELMD carries more volatility with a beta of 0.51 — expect wider price swings.
ELMD is growing revenue faster at 11.6% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ELMD scores higher overall (70/100 vs 60/100), backed by strong 15.3% margins and 11.6% revenue growth. AZN offers better value entry with a 18.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Electromed Inc
HEALTHCARE · MEDICAL DEVICES · USA
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high-frequency chest wall oscillation (HFCWO) therapy in lung care for patients of all ages in the United States. and internationally. The company is headquartered in New Prague, Minnesota.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?